Scholarlink

Background <p>Real-world evidence of aflibercept 8 mg in treatment-experienced patients remains limited. This study evaluated early outcomes of switching treatment-refractory patients with neovascular age-related macular degeneration (nAMD) to aflibercept 8 mg.</p> Methods <p>This retrospective cohort study analysed previously-treated patients who switched to aflibercept 8 mg between January and June 2025. Best-corrected visual acuity (BCVA), central macular thickness (CMT), pigment epithelial detachment (PED) height, macular fluid status and treatment intervals were evaluated at baseline, 3 months, 6 months and final visit.</p> Results <p>58 patients (66 eyes) were included. Patients received a mean 24.98 ± 18.04 anti-VEGF injections per eye over 49.41 ± 35.74 months pre-switch. Mean 5.15 ± 1.51 aflibercept 8 mg injections were administered per eye over a mean follow-up period of 25.86 ± 8.34 weeks. Median treatment intervals increased significantly from baseline to final visit (4&#xa0;to 6 weeks, <i>p</i> &lt; 0.001). 23 eyes (34.8%) achieved ≥8–week intervals by final follow-up. Median BCVA remained stable (70 ETDRS letters, interquartile range [IQR] 62–76 baseline and final follow-up, <i>p</i> = 0.571), as did median CMT (230.5 μm (IQR 189.5–281.2) at baseline to 226.5 μm (IQR 195–257) at final follow-up, <i>p</i> = 0.494). Median PED height showed a significant reduction (175 μm (IQR 106–287) at baseline to 173 μm (IQR 105–251) at final follow-up, <i>p</i> = 0.045). Complete macular fluid resolution occurred in 23.9% of eyes with baseline fluid at the final visit. No serious ocular adverse events occurred in this cohort.</p> Discussion <p>Aflibercept 8 mg demonstrated modest interval extension with stable functional and anatomical outcomes in heavily pre-treated nAMD patients. Long-term studies are needed to establish durability.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Early real-world outcomes of aflibercept 8 mg in previously treated neovascular age-related macular degeneration

  • 期刊论文

  • 发表日期：

    2026年4月14日

查看全文
  • Imran Karim Janmohamed,
  • Havena Harahn,
  • Barnaby Carr,
  • Saleh Sahbi,
  • Hasan Ahmed,
  • Abdelrahman Farahat,
  • Shabeeba Hannan,
  • Luke Membrey

摘要

Background

Real-world evidence of aflibercept 8 mg in treatment-experienced patients remains limited. This study evaluated early outcomes of switching treatment-refractory patients with neovascular age-related macular degeneration (nAMD) to aflibercept 8 mg.

Methods

This retrospective cohort study analysed previously-treated patients who switched to aflibercept 8 mg between January and June 2025. Best-corrected visual acuity (BCVA), central macular thickness (CMT), pigment epithelial detachment (PED) height, macular fluid status and treatment intervals were evaluated at baseline, 3 months, 6 months and final visit.

Results

58 patients (66 eyes) were included. Patients received a mean 24.98 ± 18.04 anti-VEGF injections per eye over 49.41 ± 35.74 months pre-switch. Mean 5.15 ± 1.51 aflibercept 8 mg injections were administered per eye over a mean follow-up period of 25.86 ± 8.34 weeks. Median treatment intervals increased significantly from baseline to final visit (4 to 6 weeks, p < 0.001). 23 eyes (34.8%) achieved ≥8–week intervals by final follow-up. Median BCVA remained stable (70 ETDRS letters, interquartile range [IQR] 62–76 baseline and final follow-up, p = 0.571), as did median CMT (230.5 μm (IQR 189.5–281.2) at baseline to 226.5 μm (IQR 195–257) at final follow-up, p = 0.494). Median PED height showed a significant reduction (175 μm (IQR 106–287) at baseline to 173 μm (IQR 105–251) at final follow-up, p = 0.045). Complete macular fluid resolution occurred in 23.9% of eyes with baseline fluid at the final visit. No serious ocular adverse events occurred in this cohort.

Discussion

Aflibercept 8 mg demonstrated modest interval extension with stable functional and anatomical outcomes in heavily pre-treated nAMD patients. Long-term studies are needed to establish durability.